ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Adimmune (4142.TW)
Adimmune stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · Taiwan Stock Exchange · Taiwan
NT$17.55▼ -1.40%
Prices as of Oct 27, 2026 · TWD
Chance of rising in 1 month
52%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Adimmune in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Adimmune
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Adimmune a 52% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between NT$16.88 and NT$18.37; in 9 out of 10, between NT$15.67 and NT$19.79. Estimated annual volatility is 22%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- NT$7.8B
- Market cap (USD)
- $241M
- 52-week high
- NT$22.50
- 52-week low
- NT$16.40
- Revenue (12 months)
- NT$1.4B
- Gross margin
- 23.1%
- Operating margin
- -258.7%
- Net margin
- -10.5%
- Beta
- 0.27
What this means
ATLAS does not publish a fair value for 4142.TW right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 4142.TW has traded between NT$16.40 and NT$22.50. Today it is 22.0% below that high and 7% above its low.
Its beta is 0.27: it tends to move less than the market.
About the company
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally.
Want to see everything about Adimmune?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Adimmune do?
Adimmune Corporation engages in the development, manufacture, and distribution of vaccines and other biological products in Taiwan, the United States, China, and internationally.
What is the chance 4142.TW goes up next month?
52%: close to a coin flip. In half of the simulated outcomes, 4142.TW ends the month between NT$16.88 and NT$18.37.
How big is Adimmune and what is its P/E ratio?
Adimmune's market capitalization is NT$7.8B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 4142.TW?
ATLAS estimates annual volatility at 22%. In a typical month, half of the outcomes end between NT$16.88 and NT$18.37.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer